The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback